You are here

Risk And Outcomes Of COVID-19 Patients Exposed To Immunosuppressive And Immunomodulatory Agents In British Columbia. A Population-Based Study.

COVID-19 Research Area(s): Diagnostics, Genomics & Transmission Dynamics, Healthcare Delivery & Policy

To be better prepared for the second wave of COVID-19 in BC, we need to understand the risk factors influencing contracting the infection and its outcome in infected people, especially in vulnerable people, such as patients with auto-immune diseases, cancer or those with transplants who are being treated with immunosuppressive or immunomodulatory agents (IIA).

Patients using IIA for their care have raised fears about being at a greater risk of contracting COVID-19 as these medications lower the immune system. Also, they have uncertainties as IIA are being used to treat COVID-19.

In this study, we will assess: 

  1. The risk of COVID-19 infection among individuals who use IIA in BC,
  2. The risk of serious outcomes among COVID-19 patient who use IIA compared to patients who do not use IIA.
Post date: 
Jun 9, 2020